Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 0123 plus carboplatin in advanced solid tumors
NL-OMON58996Phase 1Completed
- Sponsor
- Debiopharm
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zedoresertib in Nonhematologic neoplasms, sponsored by Debiopharm. Primary endpoint: Primary endpoint(s) deferred public disclosure. Started May 2019; status: completed.
02
Drugs
zedoresertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON58996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58996.